Indication

Alveolar soft part sarcoma

Alveolar soft part sarcoma is an exceedingly rare, indolent, but clinically aggressive malignant neoplasm of soft tissue that most commonly affects adolescents and young adults. Read more about Alveolar soft part sarcoma

2 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Alveolar soft part sarcoma therapies.

Showing 1–2 of 2 drugs

TECENTRIQ (atezolizumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·SMALL CELL LUNG CARCINOMA·+8
GENENTECH
Filter & compare in the drug finder →Opens the drug finder with Alveolar soft part sarcoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Alveolar soft part sarcoma.

Alveolar soft part sarcoma is an exceedingly rare, indolent, but clinically aggressive malignant neoplasm of soft tissue that most commonly affects adolescents and young adults.

It classically arises within the deep connective tissues or skeletal muscles of the extremities—predominantly the lower limbs—in adults, while frequently presenting in the head and neck region, particularly the orbit or tongue, in children.

Pathophysiologically, it is defined by an unbalanced translocation, der(17)t(X;17)(p11.2;q25), which creates the pathogenic *ASPSCR1–TFE3* gene fusion and leads to dysregulated transcription.

Histopathologically, tumors demonstrate organoid or nested pseudoalveolar architectures of large cells accompanied by prominent vascularity, predisposing patients to early hematogenous metastases, most commonly to the lungs, brain, and bones.

Personalize your experience

Follow Alveolar soft part sarcoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it